SCH 530348 is now vorapaxar (thrombin receptor antagonist)

What used to be a Schering-Plough pipeline drug is now a Merck pipeline drug. SCH 530348 is now vorapaxar and it's a new oral antiplatelet medication called a thrombin receptor antagonist, or TRA. If you're a cardiologist, you've probably heard of this compound.  If you look for it on ClinicalTrials.gov, you'll find the following studies:

• Trial to Assess the Safety and Effects of SCH 530348 in Japanese Subjects With Acute Coronary Syndrome (P04772)(COMPLETED)
• Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA•CER) (Study P04736AM2)
• Trial to Assess the Safety of SCH 530348 in Japanese Subjects With Cerebral Infarction (Study P05005AM5)(COMPLETED)
• Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (Study P04737AM2)
• Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573AM1) (COMPLETED)
• Trial to Assess the Ocular Safety of SCH 530348 in Patients With Atherosclerosis (Study P05183AM1)